Abstract
Sixty patients with early chronic phase CML (ECPCML) received Nilotinib on a phase II study which included a comparison of the Xpert BCR-ABL Monitor™ PCR system with standardized (IS) BCR-ABL1 real-time quantitative PCR (RQ-PCR). 88% patients achieved MMR with 45% achieving MR4.5. At 3 months BCR-ABL1/ABL1 IS >1% and <10% was associated with a lower likelihood of subsequent MR4.5 compared to patients with lower levels (p = 0.018). No significant difference was observed between methodologies in identifying MMR. Nilotinib induces high molecular response rates in ECPCML and the Xpert BCR-ABL Monitor™ system merits further investigation in this setting.
Original language | English |
---|---|
Pages (from-to) | 310-315 |
Journal | Leukemia research |
Volume | 38 |
Issue number | 3 |
Early online date | 01 Dec 2013 |
DOIs | |
Publication status | Published - Mar 2014 |
Bibliographical note
Copyright © 2013 Elsevier Ltd. All rights reserved.ASJC Scopus subject areas
- Cancer Research
- Hematology
- Oncology